Eyepoint Pharmac Stock Price, News & Analysis

EyePoint Pharmaceuticals (NASDAQ: EYPT) provided a business update and clinical timelines for 2023, highlighting ongoing Phase 2 trials for its lead product EYP-1901, targeting wet AMD and NPDR. The company estimates 2022 net product revenue exceeding $39.5 million, up from $35.3 million in 2021, with cash reserves around $144 million. Key milestones include topline data from the DAVIO 2 trial expected in 4Q 2023. However, changes in Medicare reimbursement for DEXYCU may significantly impact future revenues.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the promotion of Dr. Jay S. Duker to President while retaining his role as Chief Operating Officer. Dr. Duker has been instrumental in leading the company’s clinical pipeline, achieving positive results in the Phase 1 DAVIO trial for wet age-related macular degeneration (AMD) and initiating two Phase 2 trials for the investigational drug EYP-1901. EyePoint focuses on developing treatments for serious eye disorders, leveraging its Durasert® technology for sustained drug delivery.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced on December 15, 2022, the grant of non-statutory stock options to a new employee as an inducement award. The company issued options to purchase up to 3,000 shares at an exercise price of $2.68 per share, based on the stock's closing price on the grant date. The options vest over four years, with a quarter vesting after one year and the rest in monthly installments, contingent on the employee's continued service.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the grant of non-statutory stock options totaling 10,700 shares to two new employees as a part of their inducement awards. This follows NASDAQ Listing Rule 5635(c)(4) and aims to attract talent to the company. The options were granted at an exercise price of $4.42 per share, corresponding to the closing stock price on November 15, 2022. The options will vest over four years, with the first 25% vesting on the anniversary of the grant date. EyePoint is focused on developing treatments for serious eye disorders using its Durasert® technology.

EyePoint Pharmaceuticals (NASDAQ: EYPT) announced participation in several upcoming conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 14, 2022, the Stifel 2022 Healthcare Conference on November 16, 2022, and BTIG Ophthalmology Day on November 29, 2022. Webcasts of these presentations will be available for replay on the company's website. EyePoint focuses on therapeutics for serious eye disorders, leveraging its Durasert® technology, including EYP-1901, currently in Phase 2 trials.

EyePoint Pharmaceuticals (EYPT) announced its Q3 2022 financial results, reporting net product revenue of $9.7 million, a 13% increase from Q3 2021. The company initiated two Phase 2 clinical trials for EYP-1901 targeting wet AMD and NPDR. Management stated that these trials stem from positive Phase 1 results, presented at major ophthalmology meetings. Operating expenses rose to $28.4 million, while net loss reached $18.4 million or ($0.49) per share. The company anticipates funding through mid-2024, supported by its cash reserves of $157.3 million.

EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call and live webcast on November 2, 2022, at 8:30 a.m. ET to report its Q3 2022 financial results and discuss corporate developments. The company focuses on developing therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained intraocular drug delivery. Currently, EYPT is advancing EYP-1901, a Phase 2 clinical trial treatment. The call will be accessible via a registration link and a replay will be available on the company's website after the event.

On October 14, 2022, EyePoint Pharmaceuticals (NASDAQ: EYPT) granted non-statutory stock options to 12 new employees, totaling 42,900 shares. The options have an exercise price of $5.60 per share, coinciding with the closing stock price on that date. These options are part of a strategy to attract talent and are subject to a four-year vesting schedule. EyePoint's proprietary Durasert technology is being utilized in their pipeline, notably EYP-1901, which is in Phase 2 trials for sustained delivery of anti-VEGF treatment. The company focuses on therapeutics for serious eye disorders.

EyePoint Pharmaceuticals (NASDAQ: EYPT) has initiated the first patient dosing in the Phase 2 PAVIA clinical trial for EYP-1901, targeting non-proliferative diabetic retinopathy (NPDR). This trial aims to evaluate the treatment's efficacy and safety in approximately 105 patients. EYP-1901 utilizes a sustained delivery method to potentially improve vision and reduce complications. Phase 1 results showed promising safety and efficacy, with significant percentages of patients not needing further anti-VEGF injections. The trial's primary endpoint is a two-level improvement in diabetic retinopathy severity by week 36.